Press releases – Oncopeptides

Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma

October 1, 2020 - Other press release

STOCKHOLM — October 1, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the open-label Expanded Access Program, sEAPort (https://oncopeptides-us.com/en/expanded-access-program/), for ...

Oncopeptides further aligns the US and global organizational structure and appoints Mohamed Ladha as General Manager of the US Business Unit

September 8, 2020 - Other press release

STOCKHOLM — September 8, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has eliminated an organizational layer to shorten the decision-making process in the US ...

Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma – 495 patients included

September 4, 2020 - Other press release

STOCKHOLM — September 4, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the last patient has been successfully enrolled in the pivotal phase 3 study OCEAN in relapsed refractory mul...

FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

August 29, 2020 - Regulatory press release

STOCKHOLM — August 29, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the US Food and Drug Administration, FDA, has granted priority review for Oncopeptides´ New Drug Applica...

INTERIM REPORT Q2 2020

August 26, 2020 - Regulatory press release

Summary Financial overview April 1 – June 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 401.0 M (loss: 171.9) Loss per share, before and after dilution, was SEK 6.79 (loss: 3...

Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study

August 7, 2020 - Other press release

STOCKHOLM — August 7, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the first patient has been enrolled in the Immunoglobulin Light Chain (AL) amyloidosis (OP-201) study. Thi...

Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma

August 4, 2020 - Regulatory press release

STOCKHOLM — August 4, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announced that the first patient has been enrolled in the phase 2 PORT study. The study, which is expected to be fully rec...

Number of shares and votes in Oncopeptides

July 31, 2020 - Regulatory press release

Stockholm —July 31, 2020 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being registered due to the dir...

Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO

June 30, 2020 - Regulatory press release

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J...

Number of shares and votes in Oncopeptides

June 30, 2020 - Regulatory press release

Stockholm — June 30, 2020 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incen...

Oncopeptides submits a New Drug Application to the FDA for accelerated approval of melflufen in triple-class refractory multiple myeloma patients

June 30, 2020 - Regulatory press release

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company submits a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for acc...

Oncopeptides strengthens the pre-clinical development and takes over Kancera´s Solna-based laboratory for drug development as of July 1

June 29, 2020 - Other press release

STOCKHOLM — June 29, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company has agreed with Kancera to take over Kancera’s drug development facility in Solna, Sweden. The agreem...

Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients

June 15, 2020 - Other press release

STOCKHOLM — June 15, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination wit...

Oncopeptides hosts a virtual symposium at the 25[th] European Hematology Association Congress on Challenges in Managing Patients with Myeloma

June 11, 2020 - Other press release

STOCKHOLM — June 11, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company hosts a symposium at the EHA 25 Virtual Edition on June 13[th], focusing on the “Challenges in Manag...

New analysis confirms that multiple myeloma patients in the OCEAN study stay on treatment longer than previously estimated – results expected H1-2021

June 1, 2020 - Regulatory press release

STOCKHOLM — June 1, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that patients in the OCEAN study stay on treatment longer than previously estimated. As a consequence, top-line results are...

Number of shares and votes in Oncopeptides

May 29, 2020 - Regulatory press release

Stockholm —May 29, 2020 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being registered due to the dir...

Oncopeptides reinitiates patient enrollment to the melflufen clinical program following a temporary pause due to the COVID-19 pandemic

May 28, 2020 - Regulatory press release

STOCKHOLM — May 28, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that the company starts patient enrollment to its clinical program following the temporary recruitment pause due to the COV...

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

May 26, 2020 - Regulatory press release

Stockholm, Sweden – 26 May 2020 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2020 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolu...

Interim Report Q1 2020

May 26, 2020 - Regulatory press release

Summary Financial overview January 1 – March 31, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 297.3 M (loss: 134.1) Loss per share, before and after dilution, was SEK 5.37 (...

Oncopeptides completes enrollment to the pivotal phase 3 study OCEAN for relapsed refractory multiple myeloma – 450 patients included

May 22, 2020 - Regulatory press release

STOCKHOLM — May 22, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces a successful completion of enrollment in the pivotal phase 3 study OCEAN for the treatment of relapsed refractory multiple mye...

Oncopeptides presents pre-clinical melflufen data at the AACR Annual Meeting 2020 that further validates the technical platform, PDC

May 15, 2020 - Other press release

STOCKHOLM — May 15, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that new pre-clinical data evaluating the potential of the lead candidate melflufen (melphalan flufenamide) have bee...

Oncopeptides announces new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting

May 14, 2020 - Other press release

STOCKHOLM — May 14, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that data from the pivotal phase 2 study HORIZON, and additional clinical and preclinical data that further evaluate the...

Oncopeptides announces that two abstracts on multiple myeloma have been accepted by the 2020 ASCO Annual Meeting

May 13, 2020 - Other press release

STOCKHOLM — May 13, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that two abstracts with data in multiple myeloma have been accepted by the 2020 American Society of Clinical Oncology (ASCO) Ann...

Oncopeptides has completed a directed share issue raising approximately SEK 1,414 million (USD 144 M)

May 6, 2020 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA,...

Oncopeptides intends to carry out a directed share issue

May 5, 2020 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA,...

Oncopeptides Annual Report 2019

April 28, 2020 - Regulatory press release

Stockholm – April 28, 2020 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the annual report for 2019 is now available on the company's website. The report summarizes the company's bus...

Annual General Meeting in Oncopeptides AB (publ)

April 22, 2020 - Other press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual ...

Oncopeptides strengthens its corporate communications function by appointing Rolf Gulliksen as Global Head of Corporate Communications

April 2, 2020 - Other press release

STOCKHOLM — April 2, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Rolf Gulliksen has been appointed global head of corporate communications. Rolf has 30 years of experience fro...

Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study

March 26, 2020 - Regulatory press release

STOCKHOLM — March 26, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today the final topline results from the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple mye...

The Lancet Haematology Publishes Results from Oncopeptides’ Multicenter, International Phase 1/2 Study (O-12-M1)

March 24, 2020 - Other press release

Stockholm — March 24, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the publication of results from its O-12-M1 study, melflufen plus dexamethasone in relapsed/refractory multiple mye...

Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program

March 20, 2020 - Regulatory press release

STOCKHOLM — March 20, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today measures the company is taking in response to the global spread of the novel coronavirus (COVID-19) pandemic. Most imp...

Oncopeptides strengthens its organization by appointing Karolina Vilval as General Counsel

March 2, 2020 - Other press release

STOCKHOLM — March 2, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karolina Vilval has been appointed as General Counsel of Oncopeptides. Karolina has 15 years of experience fro...

Interim Report Q4 2019

February 20, 2020 - Regulatory press release

Summary Financial overview October 1 – December 31, 2019 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 244,9 M (loss: 112.0) Loss per share, before and after dilution, was SEK 4.42 (...

Oncopeptides will host a webcast on Monday, January 27th at 11.00 (CET)

January 24, 2020 - Other press release

STOCKHOLM — January 24, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that it will host a webcast at 11am (CET) on Monday, January 27[th] 2020 where CEO Jakob Lindberg will present and...

Oncopeptides strengthens its regulatory function by appointing Karin Eklund Vanderpol as Head of Regulatory Affairs

January 7, 2020 - Other press release

STOCKHOLM — January 7, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karin Eklund Vanderpol has been appointed as head of regulatory affairs of Oncopeptides. Karin has 20 years of ...

Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)

December 17, 2019 - Regulatory press release

Stockholm, Sweden – 17 December 2019 – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General Meeting, the foll...

Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019

December 8, 2019 - Regulatory press release

STOCKHOLM — December 8, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In ...

Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019

December 7, 2019 - Regulatory press release

STOCKHOLM — December 7, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an ...

Oncopeptides will host a webcast on Tuesday, December 10[th] at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting

December 6, 2019 - Other press release

Stockholm – December 6, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10[th], 2019, at 13:00 (CET) to provide an update reg...

Oncopeptides appoints Joseph Horvat as President North America

December 2, 2019 - Other press release

Stockholm – December 2, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Joseph Horvat has been appointed as President North America and CEO of Oncopetides Inc. Joseph will serve o...

Interim Report Q3 2019

November 19, 2019 - Regulatory press release

Summary Financial overview July 1 – September 30, 2019 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 189.8 M (loss: 94.0) Loss per share, before and after dilution, was SEK 3.53 (...

Extraordinary General Meeting in Oncopeptides AB (publ)

November 14, 2019 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend an Extr...

Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019

November 6, 2019 - Other press release

STOCKHOLM — November 6, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple myeloma and Light Chain (AL...

Number of shares and votes in Oncopeptides

October 31, 2019 - Regulatory press release

Stockholm — 31 October 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the...

Nomination Committee appointed in respect of AGM 2020 in Oncopeptides

October 10, 2019 - Regulatory press release

Stockholm - October 10, 2019 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on May 21st, 2019, the Nomination...

Number of shares and votes in Oncopeptides

September 30, 2019 - Regulatory press release

Stockholm — 30 September 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the...

Patient recruitment in the Pivotal Phase 2-Study HORIZON completed

September 26, 2019 - Other press release

Stockholm - September 26, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the last patient has been included in the OP-106 HORIZON pivotal phase 2 clinical study evaluating melflufen...

Exercise of options and sale of shares under the Employee Stock Option Program 2012/2019

September 24, 2019 - Regulatory press release

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that all stock options 1) held by management team members under the Employee Stock Option Program 2012/2019 with associated warrants...

New Interim Data in RRMM Patients with Extramedullary Disease from the Pivotal Phase 2 Horizon-study presented at International Myeloma Workshop

September 15, 2019 - Regulatory press release

Stockholm – September 15, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing pivotal Phase 2 study, HORIZON, at the 17th International M...

Oncopeptides Announces Two Poster Presentations at the International Myeloma Workshop

September 14, 2019 - Other press release

Stockholm – September 14, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that our two poster presentations have been made public at the 17th International Myeloma Workshop (IMW) m...

Data from Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting

September 11, 2019 - Other press release

Stockholm – September 11, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that clinical trial data were presented at the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting in ...

New updated data will be presented from Oncopeptides’ Pivotal Phase 2 HORIZON study in patients with extra medullary disease (EMD) on September 15th

August 30, 2019 - Other press release

Stockholm - 30 August 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that new updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study will be presented at at the 17th...

Interim Report Q2 2019

August 28, 2019 - Regulatory press release

Summary

Oncopeptides appoints Klaas Bakker as new Chief Medical Officer

August 20, 2019 - Regulatory press release

Stockholm - August 20, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announces that Klaas Bakker has been appointed as the new Chief Medical Officer (CMO) for Oncopeptides, starting...

Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15

August 16, 2019 - Other press release

Stockholm – August 16, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal O...

Number of shares and votes in Oncopeptides

July 31, 2019 - Regulatory press release

Stockholm — 31 July 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 5,015,000 shares, whi...

Oncopeptides has completed a directed share issue of approximately SEK 727 million (USD 78 M)

June 28, 2019 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, ISRAEL, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Oncopeptides intends to make a directed share issue

June 27, 2019 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, ISRAEL, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

June 16, 2019 - Regulatory press release

Stockholm - 16 June 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. The oral presentation was included...

New Data Presented at 24th EHA Congress from Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

June 14, 2019 - Regulatory press release

Stockholm - 14 June 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO), announced today new data presented at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, including updated...

Oncopeptides will host a Webcast on Monday, 17 June at 09:00 (CET) to review and update presentations from European Hematology (EHA) meeting

June 13, 2019 - Other press release

Stockholm – 13 June 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will make a review and update on the presented data from the European Hematology Meeting (EHA) on ...

New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting

June 3, 2019 - Other press release

Stockholm - 3 June 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers, announced today...

Oncopeptides to present at the Jefferies Healthcare Conference in New York on June 7th at 11.30am EST

May 28, 2019 - Other press release

Stockholm – May 28, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will attend the Jefferies annual Healthcare Conference in New York between June 4-7th and make a plenum pre...

BULLETIN FROM THE ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

May 21, 2019 - Regulatory press release

Stockholm, Sweden – 21 May 2019 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2019 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolu...

Interim Report Q1 2019

May 21, 2019 - Regulatory press release

Summary of Q1 “The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides.”

Oncopeptides to Apply for Accelerated Approval in the US

May 20, 2019 - Regulatory press release

Stockholm – May 20, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that, after discussions with the FDA, the company has initiated the preparation for submitting a New Drug Application (...

Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019

May 16, 2019 - Regulatory press release

Stockholm – May 16, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that a total of four abstracts have been accepted for presentation at the 24th Congress of European Hematology Association (...

Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting

May 15, 2019 - Regulatory press release

Stockholm – May 15, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to ...

Oncopeptides Annual Report for 2018

April 26, 2019 - Regulatory press release

Stockholm – 26 April 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Annual Report for 2018 now is available at the company’s website, www.oncopeptides.com and can be found under...

Oncopeptides provides new guidance on the patient recruitment in the OCEAN study and a clinical program update in a webcast at 10:00 (CET)

April 24, 2019 - Regulatory press release

Stockholm – 24 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the company will provide an update on patient recruitment in the ongoing phase 3 study OCEAN, as well as a general u...

ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

April 16, 2019 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual ...

Updated financial calendar

April 11, 2019 - Other press release

Stockholm - April 11, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has updated its financial calendar, the interim report for Q2 2019 have been moved to 28 August. The dates...

Additional patent protection for melflufen granted in the US until 2033

April 10, 2019 - Other press release

Stockholm - 10 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides...

Data from Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting

February 27, 2019 - Other press release

Stockholm — 27 February 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that data from its Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company’s...

Oncopeptides to present at the Cowen and Company Annual Healthcare Conference on Monday 11th March at 4:10 pm Eastern Standard Time

February 25, 2019 - Other press release

Stockholm – February 25, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Jakob Lindberg, CEO at Oncopeptides, will present the company at Cowen and Company 39th Annual Healthcare Con...

Year-end Report 2018

February 22, 2019 - Regulatory press release

Summary of Q4 Financial overview October 1 – December 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 111.4 M (loss: 66.2) Loss per share, before and after dilution, was 2.53 (...

Oncopeptides will host a webcast in conjunction with its Year-end Report 2018 on 22 February at 14:00 (CET)

February 18, 2019 - Other press release

Stockholm —18 February 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Company will release its Year-end Report on 22 February at 8:00 am CET. The report will be available on ...

Number of shares and votes in Oncopeptides

January 31, 2019 - Regulatory press release

Stockholm —31 January, 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 4,750,000 shares, whi...

Oncopeptides has completed a directed share issue of approximately SEK 546 million

January 24, 2019 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE...

Oncopeptides intends to make a directed share issue

January 23, 2019 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Oncopeptides Capital Markets Day December 14th in New York

December 13, 2018 - Other press release

Stockholm – December 13, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) will hold its Capital Markets Day in New York tomorrow, Dec 14, between 14:30 – 17:00 CET (8:30-11:00 ET). For those who canno...

Bulletin from the Extraordinary General Meeting in Oncopeptides AB (PUBL)

December 5, 2018 - Regulatory press release

Stockholm, Sweden –December 5, 2018 – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General Meeting, the foll...

Program for Oncopeptides Capital Markets Day December 14th, 2018

December 5, 2018 - Other press release

Stockholm – December 5, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) have previously announced that they will host a Capital Markets Day in New York. The program is now available below and on the c...

Interim data from the ongoing HORIZON trial with melflufen presented in an oral presentation at the 60th American Society of Hematology Meeting

December 3, 2018 - Regulatory press release

Stockholm – December 3, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Professor Paul G. Richardson presented updated interim data with melflufen (Ygalo®) from the ongoing HORIZON tria...

Oncopeptides presents first interim data from the ongoing combination trial ANCHOR with melflufen at the 60th American Society of Hematology Meeting, ASH

December 1, 2018 - Regulatory press release

Stockholm – December 1, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today a presentation of the first interim data with melflufen (Ygalo®) from the ongoing phase I/II study ANCHOR at the ...

Number of shares and votes in Oncopeptides

November 30, 2018 - Regulatory press release

Stockholm — 30 November, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the com...

Additional steps towards the commercialization of Ygalo®

November 5, 2018 - Other press release

Stockholm - 5 November 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the notice for an Extraordinary General Meeting in which the Nomination Committee is proposing one new candidate for...

Extraordinary General Meeting in Oncopeptides AB (publ)

November 5, 2018 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting to be held at Tändstickspalatset, Västra T...

Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018

November 1, 2018 - Regulatory press release

Stockholm – 1 November 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the abstracts for the 60th American Society of Hematology (ASH) meeting (December 1st-4th, San Diego, California) hav...

Number of shares and votes in Oncopeptides

October 31, 2018 - Regulatory press release

Stockholm —October 31, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the com...

Interim Report July – September 2018

October 26, 2018 - Regulatory press release

“Broad based progress”

Oncopeptides to host a Capital Markets Day in New York on December 14th

October 25, 2018 - Other press release

Stockholm – October 25, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will host a Capital Markets Day on December 14th between 8.30-11.00 AM ET in New York. Speakers will in...

Nomination Committee appointed in respect of AGM 2019 in Oncopeptides

October 15, 2018 - Other press release

Stockholm - October 15, 2018 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 17 May 2018, the Nomination Committee...

Oncopeptides to present at the Jefferies London Healthcare Conference on November 14th

October 12, 2018 - Other press release

Stockholm – October 12, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies London Healthcare Conference on November 14th at 3.20 PM local time (GMT), t...

First patient starts treatment with Ygalo® in Oncopeptides’ Phase II study BRIDGE in RRMM patients with renal impairment

September 18, 2018 - Other press release

Stockholm – 18 September 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company's Phase II BRIDGE trial designed to study the Pharmacokinetics (PK...

Number of shares and votes in Oncopeptides

August 31, 2018 - Regulatory press release

Stockholm —31 August, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incen...

Anders Martin-Löf has been appointed as the new CFO of Oncopeptides

August 9, 2018 - Regulatory press release

Stockholm – August 9, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Anders Martin-Löf, has been appointed as the new CFO of Oncopeptides and will join the company in No...

Number of shares and votes in Oncopeptides

July 31, 2018 - Regulatory press release

Stockholm —31 July, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incen...

Interim Report April-June 2018

July 13, 2018 - Regulatory press release

“General knowledge and understanding of Oncopeptides and our clinical strategy has greatly increased during the spring”

Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo® at the 23rd Congress of The European Hematology Association (EHA)

June 15, 2018 - Regulatory press release

Stockholm – June 15, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they are presenting updated interim data with Ygalo® (melflufen) from the ongoing HORIZON trial at the 23rd EH...

Oncopeptides to present at the Jefferies Healthcare Conference in New York on June 7th

May 29, 2018 - Other press release

Stockholm – May 29, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies annual Healthcare Conference in New York on June 7th at 1.30PM EST, the presentation w...

Bulletin from the Annual General Meeting in Oncopeptides AB (Publ)

May 17, 2018 - Regulatory press release

Stockholm, Sweden – 17 May 2018 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2018 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolu...

Oncopeptides AB Interim report January – March 2018

May 17, 2018 - Regulatory press release

Stockholm — May 17, 2018 — Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2018 report.

Oncopeptides has appointed a Clinical Advisory Board consisting of internationally recognized researchers within clinical development in hematology

April 23, 2018 - Other press release

Stockholm – April 23 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announced that the company has appointed a Clinical Advisory Board. The aim is to identify development opportunities both wit...

Oncopeptides Annual Report for 2017

April 18, 2018 - Regulatory press release

Stockholm – April 18 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Annual Report for 2017 now is available at the company’s website: www.oncopeptides.com.

Preparing for commercialisation of Ygalo®

April 18, 2018 - Other press release

Stockholm - 18 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) yesterday announced the notice for the AGM in which the Nomination Committee is proposing two new candidates for the Board of Directors....

ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

April 17, 2018 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra T...

First patient starts treatment in Oncopeptides’ Phase I / II ANCHOR study with Ygalo®

April 12, 2018 - Other press release

Stockholm - 12 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company's Phase I / II ANCHOR trial designed to study Ygalo® in ...

Number of shares and votes in Oncopeptides

March 29, 2018 - Regulatory press release

Stockholm - March 29, 2018 - Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 3,980,000 shares, which...

Oncopeptides strengthens its management team with Dr Christian Jacques as EVP Clinical Strategy and Chief Scientific Officer

March 26, 2018 - Regulatory press release

Stockholm – March 26th, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has broaden its management team with the appointment of Dr Christian Jacques as Executive Vice President C...

Oncopeptides has completed a directed share issue of approximately SEK 314 million

March 22, 2018 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Oncopeptides intends to make a directed share issue

March 21, 2018 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Additional patent protection for Ygalo® granted in Japan until October 2033

March 8, 2018 - Other press release

Stockholm - March 8, 2018 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the Japanese Patent Office (JPO) recently issued a notice that they will grant an additional Japanese patent to...

Oncopeptides AB Year-end report 2017

February 22, 2018 - Regulatory press release

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the Year-end report 2017. “With increasing clinical data the possible role for Ygalo® in helping patients with myeloma beco...

Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

December 10, 2017 - Regulatory press release

Stockholm – December 10th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the first survival data were presented at the annual meeting of the American Society of Hematology from t...

Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

December 9, 2017 - Regulatory press release

Stockholm – December 9th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that interim data was presented at the American Society of Hematology from the ongoing phase II study HORIZON, t...

Oncopeptides AB Interim Report July – September 2017

November 15, 2017 - Regulatory press release

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the third quarter 2017 report. “The data from our study, O-12-M1, provides us with an increased degree of comfort regarding a p...

Oncopeptides to attend the Jefferies Healthcare Conference in London on November 16th

November 7, 2017 - Regulatory press release

Stockholm – November 7, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will attend Jefferies annual Healthcare Conference in London on November 16th.

Oncopeptides to present data from two clinical studies of Ygalo® (melflufen) at American Society of Hematology (ASH), December 9-12.

November 1, 2017 - Regulatory press release

Stockholm – November 1, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present results from two clinical studies at ASH in Atlanta, US: Final data from the phase II study c...

Nomination Committee appointed in respect of AGM 2018 in Oncopeptides

October 17, 2017 - Regulatory press release

Stockholm - October 17, 2017 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 18 May 2017, the Nomination Committee...

Oncopeptides AB Interim Report April – June 2017

August 25, 2017 - Regulatory press release

”It is gratifying that our pivotal Phase III study OCEAN commenced during the quarter, according to our strategic plan. This is a milestone for Ygalo® and for us as a company, and takes us one step cl...

First patient dosed in the pivotal phase III study OCEAN with Ygalo® (melflufen)

June 14, 2017 - Regulatory press release

Stockholm - June 14, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the first patient has been dosed in the pivotal phase III study OCEAN. The study is targeting Late-Stage Relapsed...

Bulletin from the Annual General Meeting in Oncopeptides AB (Publ)

May 18, 2017 - Regulatory press release

Stockholm, Sweden – 18 May 2017 — Oncopeptides AB’s (ONCO) annual general meeting 2017 was held today, at IVA Conference center in Stockholm. At the meeting, the following principal resolutions were passe...

Oncopeptides AB Interim Report January – March 2017

May 18, 2017 - Regulatory press release

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2017 report. ”Our IPO received strong interest both from Sweden and internationally, including several wel...

Change in number of shares and votes in Oncopeptides AB (publ)

April 28, 2017 - Regulatory press release

During April, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 977 906 shares and votes due to the new issue of shares...

Annual General Meeting in Oncopeptides AB (publ)

April 18, 2017 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438 (“Oncopeptides” or the “Company”), are hereby given notice to attend the Annual General Meeting to be held in the Banquet room at IVA Con...

Oncopeptides AB issues 977,906 shares additionally in connection with offer to acquire shares and listing on Nasdaq Stockholm (the “Offering”)

March 27, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

ABG Sundal Collier AB exercises the over-allotment option regarding 977,906 shares in Oncopeptides AB (publ)

March 24, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected.

March 22, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Fourth member of Oncopeptides’ Nomination Committee appointed for the 2017 AGM

March 22, 2017 - Other press release

Stockholm - March 22, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the composition of the Nomination Committee has now been completed.

Additional patent protection for Ygalo granted in Europe until 2032

March 21, 2017 - Regulatory press release

Stockholm - March 21, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the European Patent Office (EPO) recently issued a notice that they intend to grant an additional European patent...

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected.

March 13, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) (“Oncopeptides” or the ”Company”) that stabilisation measures regarding the Company’s shares have been effected.

March 2, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Change in number of shares and votes in Oncopeptides AB (publ)

February 28, 2017 - Regulatory press release

During February, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 16,786,215 shares and votes due to the new issues of shares that were made in...

Company’s CEO Acquires Shares in Oncopeptides

February 24, 2017 - Regulatory press release

Stockholm, Sweden - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the company's CEO, Jakob Lindberg acquired 45,000 shares in Oncopeptides for a value of SEK 1.9M in addition to the shares...

Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today

February 22, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm

February 8, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

First patients are now enrolled in HORIZON, Oncopeptides’ Phase II Clinical Trial in Late Stage Relapsed and Refractory Multiple Myeloma

January 19, 2017 - Other press release

Oncopeptides AB, a clinical stage pharmaceutical company, developing the peptidase potentiated therapy Ygalo (melflufen), announced that the clinical development program is continuing according to plan....

Notice to attend an extraordinary shareholders’ meeting in Oncopeptides AB (Publ)

January 4, 2017 - Other press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, are hereby given notice to attend an extraordinary shareholders’ meeting to be held at the company’s premises on Västra Trädgårdsgatan 15 in ...

Oncopeptides Welcomes New Board Member – Luigi Costa

August 15, 2016 - Other press release

Oncopeptides AB, a clinical stage company developing an effective, peptidase targeted therapy for the treatment of multiple myeloma announces the appointment of Luigi Costa to its Board of Directors.

Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016

July 7, 2016 - Other press release

Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – announced that clinical results from a Phase 2 study of melflufen and dexamethasone in patients with rel...

Oncopeptides prepare for pivotal Phase 3 clinical trials

April 30, 2016 - Other press release

Oncopeptides have had a number of interactions with the regulatory authorities over the last months, and as a result the company will make preparations to be ready to begin pivotal Phase 3 clinical trials...

Oncopeptides have a successful meeting with MHRA

March 31, 2016 - Other press release

Oncopeptides had a successful meeting with MHRA on March 23rd to discuss the design of the upcoming pivotal trial of melflufen in late-stage relapsed and refractory multiple myeloma patients.

Oncopeptides CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma.

January 13, 2016 - Other press release

Oncopeptides and CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma.

Oncopeptides presents latest efficacy results of melflufen in combination with dexamethasone at ASH

December 11, 2015 - Other press release

Oncopeptides AB, a clinical stage company developing a peptidase potentiated therapy – melflufen – presented clinical results from an ongoing Phase 2 study in patients with relapsed and relapsed refractory mul...

Results Presented at EHA Show Significant Clinical Benefit, as Measured by Overall Response Rate and Progression Free Survival, when Treated with Melflufen and Dexamethasone,

June 12, 2015 - Other press release

Heavily Pretreated, Relapsed and Relapsed Refractory Multiple Myeloma Patients Showed Significant Clinical Benefit, as Measured by Overall Response Rate and Progression Free Survival, when Treated with...

Oncopeptides to Present Promising Phase I/ II Clinical Data at the European Hematology Association in Vienna, Austria, June 11 – 14 2015

June 4, 2015 - Other press release

Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – today announced that the clinical results from an ongoing Phase I/II study of safety and efficacy of mel...

Oncopeptides Receives EMA and FDA Orphan Drug Designation for Melflufen in the Treatment of Multiple Myeloma

March 23, 2015 - Other press release

Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have both gra...

Oncopeptides Presents Encouraging Preliminary Phase I/ II Clinical Data with Melflufen and Dexamethasone for Patients with Relapsed and RelapsedRefractory Multiple Myeloma at the 56th ASH Annual Meeting and Exposition

December 5, 2014 - Other press release

Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that initial clinical data from the dose escalation part of a Phase I/II dose escalation/expansion tri...

Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients.

August 20, 2013 - Other press release

Stockholm, Sweden August 20, 2013 – Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma p...

Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients

May 21, 2013 - Other press release

Oncopeptides today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members...

Oncopeptides AB appoints Jakob Lindberg as CEO

October 21, 2011 - Other press release

Oncopeptides today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden...

Oncopeptides AB. Presents the New Anticancer Agent J1 at The American Society of Hematology Annual Meeting in Orlando, Florida

December 1, 2010 - Other press release

Oncopeptides today announced that preclinical results for J1 will be presented this weekend at the ASH annual meeting at a poster session on Saturday December 4th at 5:30PM.

Oncopeptides Announce New Chairman of the Board

April 19, 2010 - Other press release

Oncopeptides today announced that Alan Hulme was elected Chairman of the Board at the statutory annual meeting. Mr. Hulme has over 30 years experience in the life science business and a wide experience...